00:00University of Michigan researchers are testing a new drug combination for advanced prostate cancer.
00:05The approach targets two different pathways used by cancer cells.
00:09It could help cancers that become resistant to standard treatments.
00:13Prostate cancer affects about one in eight men during their lifetime.
00:17Researchers focused on tumors that change their cellular identity to escape treatment.
00:22This process is known as transdifferentiation.
00:25The team combined BET inhibitors with DNMT inhibitors.
00:28Together, the drugs suppressed cancer cell growth more effectively.
00:32Similar results were observed in tumors implanted in mice.
00:36The combination also reduced tumor growth at relatively low doses.
00:40Researchers say the treatment was well-tolerated by the mice.
00:44Now, scientists are searching for biomarkers to identify likely responders.
00:49They also want to see if this cancer transformation can be stopped earlier.
00:53Clinical trials will determine whether the strategy can help patients.
00:56Disclosure. This video contains stock footage and content created or enhanced using AI-assisted tools AI-generated.
